The association of HER2 overexpression with recurrence was not consistently reported in the literature [108] and it appeared to be statistically significant only for in situ LRs [106,107], suggesting that HER2 is involved in the first phases of DCIS development rather than in the pathways of invasive progression. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.